Jefferies Reiterates Buy Rating on Altimmune (ALT) as company enters 'execution stage'

March 27, 2026 10:53 AM

Jefferies analyst Roger Song reiterated a Buy rating and $28.00 price target on Altimmune (NASDAQ: ALT)The analyst commented, "Altimmune is ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found